Items for "Zevalin®"

Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives

90Y-ibritumomab tiuxetan (Zevalin) is currently approved for radioimmunotherapy of patients with relapsed or refractory follicular non-Hodgkins lymphoma pretreated with rituximab...

Keywords: Ibritumomab-Tiuxetan, Zevalin®, Yttrium-90, Radioimmuntherapie, Aktivimeter, Strahlenschutz